CLEARWATER, Fla., Sept. 26 /PRNewswire/ -- Advanced Bio-Technologies Inc (ABT) is pleased to announce that the majority shares in the corporation have been purchased by HealthEdge Investment Partners of Tampa FL. (http://www.healthedgepartners.com).
Paul Guilbaud, ABT President and CEO, commented, "This is a new stage in the exciting development of ABT. The acquisition allows us to ramp up sales and marketing in the USA, build the necessary infrastructure for our world- wide sales expansion and allow us to support our International distributors."
"This is a positive development for both ABT and HealthEdge. We believe that the synergy between our fund and the company will facilitate accelerated growth for the company. We intend to work closely with the management of ABT to grow the business organically and by using the infrastructure as a platform to acquire new brands," commented Brian Anderson, Managing Partner at HealthEdge Investment Partners.
Advanced Bio-Technologies is one of the leading companies in the rapidly growing global scar treatment market with its patented silicone-based products marketed under the brand Kelo-cote(R). Silicone is recognized as the first line of treatment for abnormal scars throughout the medical community. ABT has relocated its offices to Clearwater, Florida, where it will centralize the functions of the company to better manage its growth.
ABT has also launched its Kelo-cote(R) scar treatment line in the key European markets through 100%-owned subsidiaries in the UK and Germany. This strategic development allows ABT to have direct operations in some of the largest markets worldwide, and creates the platform for concentrating its efforts in the Plastic Surgery and Dermatology sectors. New products will ensure growth for ABT in each of those markets. "We have established a strong Kelo-cote(R) presence in the New York City, Los Angeles and Miami markets and are currently expanding our US sales team to reach other key metro areas including Tampa, Dallas, and Atlanta," stated Mr. Guilbaud.
|SOURCE Advanced Bio-Technologies Inc|
Copyright©2007 PR Newswire.
All rights reserved